| Description |
BAY 73-1449 is a selective antagonist of prostacyclin IP receptor, with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure[1].
|
| Related Catalog |
|
| Target |
IP Receptor:<0.1 nM (IC50)
|
| In Vivo |
BAY 73-1449 (0.1-1 mg/kg; i.v.) does not significantly reduce mesenteric inflow, but significantly reduces splenic shunt vessel outflow in rats[1]. BAY 73-1449 (1-5 mg/kg, s.c. once daily for 7 d) has no effects on the degree of porto-systemic shunting in rats[1]. BAY 73-1449 (1 mg/kg, s.c. once daily for 7 d), has no effects on portal pressures in rats[1]. Animal Model: Male Wistar rats (250-350 g) are ligated portal vein[1] Dosage: 0.1, 1 mg/kg Administration: A single i.v. Result: Significantly reduced shunt flow without affecting mesenteric flow.
|
| References |
[1]. Bexis S, et, al. Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat. Eur J Pharmacol. 2008 Aug 20;590(1-3):322-6.
|
